With its market launch in Jordan last year, approval and winning the government tender in Saudi Arabia, as well as further launches in other GCC markets planned for 2024, FYB201 is set to improve access to ophthalmic treatments in the MENA region. “The successful approval of FYB201 in Saudi Arabia underlines the quality of our biosimilar and its importance as an affordable treatment option for DME, one of the most common causes of severe visual impairment and blindness in the middle east,” said Nicola Mikulcik, CBO of Formycon. Read more in our press release.